Compare Adaptive Biotechnologies Corp (ADPT) vs Commvault Systems Inc (CVLT) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Commvault Systems (CVLT) trades at $150.05, up 0.05% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate. However, high valuation multiples like a P/E of 94.97 and P/B of 829.37 suggest premium pricing. Recent news highlights a class action lawsuit filed against the company, alongside positive product announcements including a #1 ranking in Gartner's 2026 backup solutions report.

Outlook remains mixed with analyst consensus leaning bullish (54.55% buy ratings) and a $128.75 price target below current levels. Key risks include the ongoing securities litigation and elevated valuations, while opportunities lie in continued earnings momentum and market leadership in data protection. Investors should weigh legal overhangs against fundamental strength.